G. Suarato

Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer

Background Trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) was compared with TAS-102 monotherapy in a randomized, open-label, phase 2 trial, and produced a stati...

T. Troiani ;

P. Incoronato ;

Ralph J. Napolitano Jr., DPM, CWSP, FACFAS;

V. Nacca ;

F. Paragliola ;

G. Suarato ;

A. Nicastro ;

A. Perrone ;

Erika Martinelli , MD, PhD;

G. Arrichiello ;

06/27/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

G. Suarato

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products